KRYS241220C110000
- 75.00
- 0.000.00%
Krystal Biotech Newsroom
Some Confidence Is Lacking In Krystal Biotech, Inc.'s (NASDAQ:KRYS) P/S
Krystal Biotech, Inc. (NASDAQ:KRYS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Unusual Options Activity: C, DAL and Others Attract Market Bets, C V/OI Ratio Reaches 519.3
EST Nov 6th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
Krystal Biotech Is Maintained at Neutral by Citigroup
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $206 to $221
Express News | Krystal Biotech Inc : Guggenheim Cuts Target Price to $195 From $200
Q3 2024 Krystal Biotech Inc Earnings Call
Krystal Biotech Faces Challenges in Scaling VYJUVEK Production Amid Regulatory Hurdles
Earnings Call: Krystal Biotech Reports Robust Q3 2024 Results
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript Summary
Krystal Biotech's Strong Financial Performance and Strategic Advancements Drive Buy Rating
Krystal Biotech | 10-Q: Q3 2024 Earnings Report
Krystal Biotech | 8-K: Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
Krystal Biotech GAAP EPS of $0.91 Beats by $0.01, Revenue of $83.84M Beats by $0.73M
Krystal Biotech 3Q EPS $0.91 >KRYS
Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q3 Revenue $83.8M
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates